A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity

Abstract

An exposure-response model has been established that quantitatively describes the relationship between systemic semaglutide exposure and weight loss and predicts weight-loss trajectories for people with overweight or obesity who are receiving semaglutide doses up to 2.4 mg once weekly.